Today's biotech startups are facing an increasingly difficult commercialization landscape. Yesterday’s antiquated approach to successful market entry and adoption, or market access, is unfortunately still pervasive, resulting in a risk of lower valuations in this already volatile environment. One of the biggest mistakes to market entry among the vast majority of companies is they start planning their go to market strategy far too late to have any meaningful impact.
Payers have very specific clinical and health economic data requirements in terms of endpoints, comparators, PROs and Quality of Life measures. By failing to take the payers’ perspective into account, biotech companies take a very significant risk that they will not meet requirements, resulting in the potential for delayed and/or restricted access, thus driving a company’s value down and depriving patients access to innovative, impactful solutions.
DREAM BIG™ is changing the way companies approach market access and reimbursement through several means, including creation of custom value-based calculators & health economic models to justify product pricing through clinical and cost-effectiveness valuations and risk-share payment frameworks to drive utility and adoption through paid pilots. This helps avoid a lot of hassle for both startups, as well as potential investors who are looking at funding them in order to drive commercialization success for innovative diagnostics, medical devices or pharmaceuticals.
Pathways to viability & commercial success can be challenging to navigate. DREAM BIG™ reinforces innovations as a source for equity and our is vision to make the latest healthcare technology accessible to everyone.
Comentários